{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:52:18Z","timestamp":1779310338155,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T00:00:00Z","timestamp":1732406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174229"],"award-info":[{"award-number":["82174229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010876","name":"Shanghai University of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010876","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3502000"],"award-info":[{"award-number":["2022YFC3502000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.gastha.2024.100593","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T03:16:15Z","timestamp":1732850175000},"page":"100593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative Efficacy of NAFLD Therapies and Biomarker Associations: A Meta-Analysis Based on Liver Fat Content"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8087-0043","authenticated-orcid":false,"given":"Haoxiang","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinhua","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingshan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lujin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10290","key":"10.1016\/j.gastha.2024.100593_bib1","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.gastha.2024.100593_bib2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.gastha.2024.100593_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.gastha.2024.100593_bib6","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.gastha.2024.100593_bib7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"7","author":"Harrison","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"27","key":"10.1016\/j.gastha.2024.100593_bib8","first-page":"9026","article-title":"Role of liver biopsy in nonalcoholic fatty liver disease","volume":"20","author":"Nalbantoglu","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastha.2024.100593_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.615978","article-title":"Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment","volume":"8","author":"Heyens","year":"2021","journal-title":"Front Med"},{"issue":"10213","key":"10.1016\/j.gastha.2024.100593_bib10","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.gastha.2024.100593_bib11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/liv.13972","article-title":"Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease","volume":"39","author":"Pelusi","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.gastha.2024.100593_bib13","series-title":"Reflection paper on regulatory requirements for the development of medicinal products for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC)","year":"2023"},{"issue":"2","key":"10.1016\/j.gastha.2024.100593_bib14","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.29797","article-title":"Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials","volume":"68","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.gastha.2024.100593_bib15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0962280207082719","volume":"17","author":"Lassere","year":"2008","journal-title":"Stat Methods Med Res"},{"issue":"8","key":"10.1016\/j.gastha.2024.100593_bib16","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamasurg.2021.0546","article-title":"PRISMA reporting guidelines for meta-analyses and systematic reviews","volume":"156","author":"Arya","year":"2021","journal-title":"JAMA Surg"},{"issue":"11","key":"10.1016\/j.gastha.2024.100593_bib17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gastha.2024.100593_bib18","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","first-page":"chap23","article-title":"Including variants on randomized trials","author":"Higgins","year":"2024"},{"issue":"757","key":"10.1016\/j.gastha.2024.100593_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.30.757.23","article-title":"Determination OF the coefficient OF correlation","volume":"30","author":"Pearson","year":"1909","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.gastha.2024.100593_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.105","article-title":"Drug discovery and treatment paradigms in nonalcoholic steatohepatitis","volume":"3","author":"Noureddin","year":"2019","journal-title":"Endocrinol Diabetes Metab"},{"issue":"3","key":"10.1016\/j.gastha.2024.100593_bib21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/0284185115580488","article-title":"A\u00a0comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease","volume":"57","author":"Idilman","year":"2016","journal-title":"Acta Radiol"},{"issue":"9","key":"10.1016\/j.gastha.2024.100593_bib22","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/17474124.2022.2127408","article-title":"The role of fibroblast growth factor 19 in the pathogenesis of nonalcoholic fatty liver disease","volume":"16","author":"Chrysavgis","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2024.100593_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/TCRM.S352008","article-title":"Fibroblast growth factor-21 as a potential therapeutic target of nonalcoholic fatty liver disease","volume":"19","author":"Raptis","year":"2023","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"10.1016\/j.gastha.2024.100593_bib24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/13543784.2020.1718104","article-title":"Fibroblast growth factor (FGF)-21 based therapies: a magic bullet for nonalcoholic fatty liver disease (NAFLD)?","volume":"29","author":"Ritchie","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"10.1016\/j.gastha.2024.100593_bib25","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.15930","article-title":"The first MASH drug therapy on the horizon: current perspectives of resmetirom","volume":"44","author":"Petta","year":"2024","journal-title":"Liver Int"},{"issue":"18","key":"10.1016\/j.gastha.2024.100593_bib26","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.3390\/diagnostics13182967","article-title":"Low-cost point-of-care monitoring of ALT and AST is promising for faster decision making and diagnosis of acute liver injury","volume":"13","author":"Chinnappan","year":"2023","journal-title":"Diagnostics"},{"issue":"3","key":"10.1016\/j.gastha.2024.100593_bib27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1055\/s-0041-1723030","article-title":"Assessing toxicity in drug trials in liver disease","volume":"41","author":"Sherman","year":"2021","journal-title":"Semin Liver Dis"},{"issue":"11","key":"10.1016\/j.gastha.2024.100593_bib28","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.gastha.2024.100593_bib29","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1089\/met.2023.0276","article-title":"Diagnostic performance of insulin resistance Indices for identifying metabolic Dysfunction-associated fatty liver disease","volume":"22","author":"Han","year":"2024","journal-title":"Metab Syndr Relat Disord"},{"issue":"10","key":"10.1016\/j.gastha.2024.100593_bib30","article-title":"HOMA-IR is an effective biomarker of non-alcoholic fatty liver disease in non-diabetic population","volume":"51","author":"Zeng","year":"2023","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.gastha.2024.100593_bib31","first-page":"351","article-title":"Assessing hepatic steatosis by magnetic resonance in potential living liver donors","volume":"30","author":"Kuru \u00d6z","year":"2024","journal-title":"Diagn Interv Radiol"},{"issue":"11","key":"10.1016\/j.gastha.2024.100593_bib32","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.21037\/qims-22-393","article-title":"The spectrum of magnetic resonance imaging proton density fat fraction (MRI-PDFF), magnetic resonance spectroscopy (MRS), and two different histopathologic methods (artificial intelligence vs.pathologist) in quantifying hepatic steatosis","volume":"12","author":"Kim","year":"2022","journal-title":"Quant Imaging Med Surg"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572324001894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572324001894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:59:29Z","timestamp":1762646369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572324001894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"alternative-id":["S2772572324001894"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2024.100593","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Efficacy of NAFLD Therapies and Biomarker Associations: A Meta-Analysis Based on Liver Fat Content","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2024.100593","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}],"article-number":"100593"}}